Back to Home

Pharmacy Value Management

Expert articles and analysis related to pharmacy value management.

185 articlesLast 7 Days

AI Summary — Last 7 Days

CMS is moving pharmacy policy from ad hoc implementation toward more durable value-management infrastructure: proposed rules would codify the Medicare Drug Price Negotiation Program and tighten product-grouping rules to close a negotiation “loophole,” while stakeholders are also pressing CMS on drug prior authorization and interoperability standards that will shape how plans, providers, and ACOs operationalize medication management. At the same time, the Trump administration’s temporary Medicare GLP-1 bridge program—offering weight-loss drugs for $50 after July 1—creates a major new cost and adherence-management pressure point for MA, Part D, and risk-bearing provider organizations if it proves politically difficult to unwind. These developments reinforce a broader shift in Part D incentives, where IRA redesign is changing formulary behavior and rebate economics, but may also create new patient-access and total-cost-of-care tradeoffs for VBC entities managing chronic disease populations. CMS negotiation rule GLP-1 bridge program

Related Articles

95ALN

FTC Takes Action to Protect Americans from Higher Drug Costs in Aurobindo, Lannett Deal - Federal Trade Commission (.gov)

FTC Takes Action to Protect Americans from Higher Drug Costs in Aurobindo, Lannett Deal  Federal Trade Commission (.gov)

FTC Health CareJun 18, 2026
95ALN

CMS Could Make Drug Price Negotiations Permanent

CMS Could Make Drug Price Negotiations Permanent - What it Means for Pharma  Pharmaceutical Commerce

Pharmaceutical CommerceJun 16, 2026
95ALN

The 340B Drug Pricing Program at a Crossroads

The 340B Drug Pricing Program at a Crossroads  JAMA

JAMA NetworkJun 16, 2026
95ALN

Colorado wins FDA approval to import prescription drugs from Canada

Colorado wins FDA approval to import prescription drugs from Canada  Becker's Hospital Review

Becker's Hospital ReviewJun 16, 2026
95ALN

The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs

By Bryce Platt, PharmD For years, Medicare Part D plans often preferred high-list/high-rebate branded multiple sclerosis (MS) drugs over lower-cost generics. That was rational behavior inside an irra...

Drug ChannelsJun 16, 2026
95ALN

CMS Proposes Permanent Rules for Medicare Drug Price Negotiation

AJMCJun 15, 2026
95ALN

Agencies issue proposed rule codifying Medicare Drug Price Negotiation Program

Agencies issue proposed rule codifying Medicare Drug Price Negotiation Program  American Hospital Association

AHAJun 15, 2026
95ALN

340B rebate model pilot advances as providers warn of added costs

The Health Resources and Services Administration (HRSA) continues to take steps toward implementing a rebate model for the 340B Drug Pricing Program. After soliciting comments on a planned model over ...

HFMAJun 15, 2026
95ALN

CMS seeks to close Medicare negotiation 'loophole'

CMS has proposed a policy change that clarifies its stance on how products are grouped together for Medicare negotiations. Under the Inflation Reduction Act, biologics become eligible for Medicare n...

Endpoints NewsJun 15, 2026
95ALN

STAT+: FDA approves Colorado’s plan to import cheaper drugs from Canada

The FDA said it will allow Colorado to import certain prescription drugs from Canada in an effort to bring prices down for residents.

STAT NewsJun 15, 2026